Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Cohort Clinical Study to Evaluate the Efficacy and Safety of Tunlametinib Combined With Anti-EGFR Monoclonal Antibody in Patients With RAS-mutated Advanced Gastrointestinal Malignancies

NCT07446270 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT07446270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07446270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Cohort Clinical Study to Evaluate the Efficacy and Safety of Tunlametinib Combined With Anti-EGFR Monoclonal Antibody in Patients With RAS-mutated Advanced Gastrointestinal Malignancies
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 3, 2026
Completion date
October 30, 2028
Enrollment
90 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

treatment for advanced colorectal cancer, treatment for advanced pancreatic cancer